{
  "url": "https://struct.news/briefs/cogent-shares-rose-14-as-six-month-cash-burn-worsened-and-dilution-widened",
  "title": "Cogent shares rose 1.4% as six-month cash burn worsened and dilution widened",
  "summary": "The biotech ended June with $181.2M in cash, but operating cash outflow reached $164.2M and diluted shares jumped 49.4%.",
  "published_at": "2026-08-10T20:25:20.110831+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "Cogent Biosciences, Inc.",
    "ticker": "COGT",
    "cik": "1193125",
    "sector": "Healthcare",
    "industry": "Biotechnology"
  },
  "source_filing": {
    "form": "10-Q",
    "filed": "2026-08-10",
    "accession": "0001193125-26-342393",
    "url": "https://www.sec.gov/Archives/edgar/data/1622229/000119312526342393/cogt-20260630.htm"
  },
  "comparison_filing": {
    "form": "10-Q",
    "filed": "2025-08-05",
    "url": "https://www.sec.gov/Archives/edgar/data/1622229/000095017025102440/cogt-20250630.htm"
  },
  "reported_figures": [
    {
      "group": "The filing in three numbers",
      "label": "Revenue",
      "value": 7871000,
      "display": "$7.9M",
      "unit": "usd",
      "period": "2020-12-31",
      "detail": null,
      "source": {
        "kind": "sec_filing",
        "label": "Filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-342393",
        "filing_date": "2026-08-10"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Revenue YoY",
      "value": -65.01622294324191,
      "display": "-65.0%",
      "unit": "percent",
      "period": "2020-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-342393",
        "filing_date": "2026-08-10"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Operating margin",
      "value": -1044.327277347224,
      "display": "-1044.3%",
      "unit": "percent",
      "period": "2020-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-342393",
        "filing_date": "2026-08-10"
      }
    }
  ],
  "watch_next": [
    {
      "type": "product_pipeline",
      "statement": "Later-stage clinical programs carry higher development costs because trials are larger and longer, making pipeline progression a durable spending sensitivity.",
      "importance": "medium",
      "evidence": "Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials.",
      "source_date": "2026-08-10"
    }
  ],
  "related_tickers": [
    "COGT"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}